137
Participants
Start Date
March 31, 2011
Primary Completion Date
December 5, 2018
Study Completion Date
December 5, 2018
NGR-hTNF
NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Placebo
Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Best Supportive Care
Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Ospedale Santo Spirito, Casale Monferrato
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria
IRCCS Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro, Genoa
Asl 3 genovese, Ospedale Villa Scassi, Genova
Istituto Clinico Humanitas, Rozzano
IRCCS Ospedale San Raffaele, Milan
IRCCS Policlinico S. Matteo, Pavia
Ospedale Ca' Foncello, Treviso
Istituto Oncologico Veneto, Padua
Azienda Ospedaliero-Universitaria di Parma, Parma
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST, Meldola
Azienda Unità Sanitaria locale di Ravenna, Ravenna
Asklepios Fachkliniken München-Gauting, München-Gauting
Zentralklinik Bad Berka GmbH, Bad Berka
Saint Petersburg State Medical University n.a. I. P. Pavlov, Saint Petersburg
Lead Sponsor
AGC Biologics S.p.A.
INDUSTRY